CompletedPhase 4NCT02752633
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
Studying Adenine phosphoribosyltransferase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Landspitali University Hospital
- Principal Investigator
- Vidar O Edvardsson, MD, M.DLandspitali - The National University Hospital of Iceland, Reykjavik
- Intervention
- Allopurinol(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2015
Study locations (1)
- Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
Collaborators
Mayo Clinic · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02752633 on ClinicalTrials.govOther trials for Adenine phosphoribosyltransferase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT02026388Rare Kidney Stone Consortium BiobankMayo Clinic
- RECRUITINGNANCT06065852National Registry of Rare Kidney DiseasesUK Kidney Association
- RECRUITINGNCT00588562Rare Kidney Stone Consortium Patient RegistryMayo Clinic
See all trials for Adenine phosphoribosyltransferase deficiency →